Products for Research Use Only
RegisterLogin

D228

CAT: 0804-HY-164670-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-164670-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].
CAS Number
2676188-98-8
UNSPSC
12352005
Target
MyD88; p38 MAPK
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/d228.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=C(C(/C(O1)=C(C)\C)=O)O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2
Molecular Formula
C22H28O12
Molecular Weight
484.45
References & Citations
[1]Tang ML, et al. From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2024 Oct 10;67 (19) :17101-17123.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-W099624S1-01Octylbenzene-d22
HY-Y0304S1-01Dibutyl phthalate-d22
HY-W707578(2R) -Sorbitan Monolauric Acid Ester-d22-1
HY-W127457S-011,2-Dihexanoyl-sn-glycero-3-phosphocholine-d22

Alternative Products

CatalogName
T200551-01D228
GTR18042079-01Six3/6 (D228) polyclonal antibody
B2023637Rabbit Polyclonal Caspase-9/CASP9 (E3-D228) Antibody (Human)

Popular Products